HOTH + 85% to $3.50: Markets are RIGGED!
1)MOST heavily traded today of ANY
80 mln as of 12 pm when only 3.3 mln out shs! Mkt Cap ~$10 mln MEANS:
2)HUGE NAKED Short Covering!
3)Positive Trial Results:
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease
PR Newswire - Tue Jun 06, 12:02PM
4)HOTH in Feb hired IntelSelect to investigate Illegal Naked Short Selling:
Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity
PR Newswire - Thu Feb 16, 1:35PM
We have been analyzing the stock market and have come up with a list of stocks that we believe are among the most manipulated in the history of the stock market.
The stock market is rigged by a combination of stock exchanges, big Wall Street banks, hedge funds, and market… pic.twitter.com/NuJfACTrY8
— InvestorTurf (@InvestorTurf) April 4, 2023
ADDITIONALLY: Payment for Order Flow
SEC Gary Gensler ~90-95% of retail orders are not processed through the lit exchange..
Lit pools, opposite of ‘dark’
$nwbo Why I believe that NWBO has been the subject of a collusion between market makers and hedge funds to artificially drive the price to levels orders of magnitude below it would be without the manipulation. https://t.co/JhsQ7cFnxC
— Larry Smith (@SmithOnStocks1) June 5, 2023
DIFFERENT STROKES for DIFFERENT FOLKS
Tell me how this can be.The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at May 9, 2023 was 3,302,113.
The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at May 9, 2023 was 3,302,113.
We know from the not-so-distant past that this one can EXPLODE!
HOPE ONE OF THESE CATCH AND RUN BETTER
WE NEED ANOTHER BIG RUNNER TO BOOST THE MARKET AGAIN
INSTEAD OF THE USUALY GAP, TRAP & GRIND
Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge
Anthony Zook, formerly of Astra Zeneca, to be named Chairman of The Board
Mike Tilton to be named Chief Executive Officer of the Combined Company
Algorithm pipeline focused on Pulmonary Arterial Hypertension (PAH) a rare disease with a
prevalence of ~100,000 patients in the US
NEW YORK, April 26, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced it has signed a Letter of Intent to merge with Algorithm Sciences, Inc. ("Algorithm") a company focused on Pulmonary Arterial Hypertension (PAH). The combined company will be named Algorithm Sciences, Inc. and be led by experienced biopharma executives, including Mike Tilton as CEO, David Cavalier as CFO and Anthony Zook, Algorithm's current chairman of the board, who will be nominated as chairman of the combined company's board of directors. Algorithm will become the majority holders of Hoth's outstanding stock by way of a merger.
"Today's announcement is an exciting chapter for Hoth and its shareholders," stated Robb Knie, CEO of Hoth. "The combination of assets in the combined company translates to additional billions of dollars in market opportunity for current shareholders. Algorithm's executive team along with its science professionals brings a seasoned executive focus on commercialization and monetization of the now robust advanced pipeline."
Mike Tilton, CEO of Algorithm commented, "Today's announced business combination achieves a new milestone for us and spotlights the tremendous opportunity of our lead therapeutic for those suffering from PAH. We are thrilled with the progress of our development program and look forward to achieving our near-term goal of filing an Investigational New Drug (IND) Application with the FDA."
The global pulmonary arterial hypertension treatment market size was valued at $7.2 billion in 2021, and is projected to reach $12 billion by 2031, growing at a CAGR of 5.2% from 2021 to 2031. (https://www.alliedmarketresearch.com/pah-treatment-market) Algorithm is uniquely positioned to take advantage of this opportunity.
On a pro forma basis and based upon the number of shares of Hoth common stock to be issued in the merger, current Hoth shareholders are currently anticipated to own approximately 14% of the combined company and current Algorithm shareholders are currently anticipated to own approximately 86% of the combined company. The Boards of Directors of both Hoth and Algorithm have unanimously approved the letter of intent. The completion of the transaction remains subject to a number of conditions, including, but not limited to, among others, the completion of due diligence to Hoth's satisfaction, the negotiation and execution of definitive documentation and satisfaction of the conditions contained therein, completion of any required stock exchange and regulatory reviews, and approval of the transaction by Hoth's stockholders and Algorithm's stockholders. Accordingly, no assurances can be made by either party that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Terms and conditions of the merger will be forthcoming as the two companies reach a definitive merger agreement.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of any business combination or stockholder meeting. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information about the Proposed Transactions and Where to Find It
In connection with the proposed transaction, and following execution of a definitive transaction agreement, Hoth will file a proxy statement with the Securities and Exchange Commission (SEC). The materials to be filed by Hoth with the SEC may be obtained free of charge at the SEC's web site at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF HOTH ARE URGED TO READ THE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products an
That looks nice I have no idea what the chart means could you explain it to me ?
Almost there. Soon the $6's.
I agree. They usually fall back to $3 or lower.
Wainwright is the worst.
whatta solid rebound $HOTH 5-8's
when I usually buy a stock and it has an offering I usually get tortured for days as it sinks lower and lower
Not this time HOTH up now 8.00
Or maybe much lower, as it happens in similar situations. We have a bunch of examples where placements destroyed the price for long time.
And this $10 millions placement constitutes 77% of company's market capitalisation! Very heavy burden for a small company.
Ouch. Those bio pumps can kick you in the butt with those post run offerings.
Huge dump today back to $5 gap.
HOTH just another POS P&D IMO.
HaloVax, LLC is a biopharmaceutical company and joint venture entity of Voltron Therapeutics, Inc. and Hoth Therapeutics, Inc.
The joint venture was announced on March 23, 2020 (click here) and plans to advance an application of VaxCelerate,
a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH),
to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection. Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.
HaloVax and Hoth, with the support of MGH, will work jointly on bringing this SAV to patients at risk of being infected with COVID-19.
The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and remove infectious agents.
The technology initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease, with the support of the Department of Defense (DoD).
These same principles are being applied to developing a vaccine against the COVID-19 pandemic.
VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting.
VaxCelerate offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens.
The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.
VaxCelerate was created by Drs. Mark Poznansky, MD, PhD, and Jeffrey Gelfand, MD,
who will continue to support its research and development, as COVID-19 has reached pandemic status. Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC)
and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific
advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting as well as to help gather additional academic and clinical KOLs to serve on the SAB.
Our goal: Generate a safe and effective vaccine with animal data in 6 months or less.
HaloVax is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccine (SAV) to patients at risk for COVID-19 infection.
We believe that our vaccine could be particularly effective and improve patient outcomes by engaging the immune system to identify and attack this pandemic infectious agent.
This technology has initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease.
This was done with the support of the DoD.
These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19
The SAV program has intellectual property surrounding composition of matter.
Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc.
The vaccine is >90% HSP70 and Aviden. Neoantigens are then incorporated to customize the vaccine.
We believe that the VaxCelerate technology has the potential to provide a differentiated approach to a COVID-19 vaccine.
|Debt/Eq no debt||0.00|